Public Outcry Follows Gilead Decision to Charge $3000 for COVID Drug that Costs Pennies to Produce

Summary:
California-based pharmaceutical giant Gilead Sciences has announced that a five-day course of its antiviral drug Remdesivir — shown in tests to effectively fight COVID-19 — will cost ,120 to Americans with health insurance and ,340 to those on Medicaid. Yet research published in April calculated that the drug could be produced at a profit for as little as %excerpt%.93 per day. The study, led by Dr. Andrew Hill from the Department of Translational Medicine, University of Liverpool, U.K., and published in the Journal of Virus Eradication, found that a five-day course of lifesaving Remdesivir could be mass-produced for less than the cost of a Subway sandwich. So cheap is the drug that the saline solution and the syringe needed to administer it would be more costly. MintPress spoke with Dr.

Topics:
Mike Norman considers the following as important:

This could be interesting, too:

Jodi Beggs writes Economists Do It With Models 1970-01-01 00:00:00

Mike Norman writes 24 per cent annual interest on time deposits: St Petersburg Travel Notes, installment three — Gilbert Doctorow

Lars Pålsson Syll writes Daniel Waldenströms rappakalja om ojämlikheten

Merijn T. Knibbe writes ´Fryslan boppe´. An in-depth inspirational analysis of work rewarded with the 2024 Riksbank prize in economic sciences.